baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC BON.CAP.CERT. 09/24 22UA/ DE000HD42107 /

8/30/2024 9:46:53 PM	Chg.0.000	Bid8/30/2024	Ask-	Underlying	Strike price	Expiration date	Option type
129.870EUR	0.00%	129.870 Bid Size: 500	- Ask Size: -	BIONTECH SE SPON. AD...	- -	9/27/2024	Call

GlobeNewswire 8/16 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...

TeleTrader 8/5 BioNTech posts revenue at €128.7 billion in Q2

GlobeNewswire 8/5 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 7/30 BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...

GlobeNewswire 7/22 BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024

GlobeNewswire 6/27 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...

GlobeNewswire 6/24 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...

GlobeNewswire 6/1 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...

GlobeNewswire 5/29 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 5/21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 5/17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

TeleTrader 5/6 BioNTech's Q1 revenue slumps 85% to €187.6M

GlobeNewswire 5/6 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 4/22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 4/7 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...

TeleTrader 3/20 BioNTech Q4 revenue plunges 65% to €1.48B

GlobeNewswire 3/20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 3/20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

GlobeNewswire 3/11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...

GlobeNewswire 3/7 BioNTech Announces Planned Retirement of Sean Marett

GlobeNewswire 3/6 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...

GlobeNewswire 2/8 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...

GlobeNewswire 1/31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...

GlobeNewswire 1/22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...

TeleTrader 1/9 BioNTech sees $3.3B revenue for 2024, expanding into oncology

UC BON.CAP.CERT. 09/24 22UA/ DE000HD42107 /

If you wish to receive reply to your feedback, please provide your email address.